Alternative Data for Nuwellis
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 28 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 52 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 14 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 27,106 | Sign up | Sign up | Sign up |
| X Followers | 1,647 | Sign up | Sign up | Sign up |
| X Mentions | 10 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 316 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 29 | Sign up | Sign up | Sign up |
| Linkedin Employees | 68 | Sign up | Sign up | Sign up |
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
| Price | $1.26 |
| Target Price | Sign up |
| Volume | 195,010 |
| Market Cap | $2.2M |
| Year Range | $1.26 - $15.95 |
| Dividend Yield | 0% |
| PE Ratio | 0.01 |
| Analyst Rating | 0% buy |
| Industry | Medical Devices |
In the news
Nuwellis, Inc. Q4 2025 Earnings Call SummaryMarch 10 - Yahoo Entertainment |
|
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial ResultsMarch 10 - GlobeNewswire |
|
Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-MarketJanuary 29 - GlobeNewswire |
|
Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio StrategyJanuary 29 - GlobeNewswire |
|
Nuwellis Announces Changes to Board of DirectorsJanuary 23 - GlobeNewswire |
|
 |
Nuwellis announces issuance of new U.S. patent on extracorporeal therapyJanuary 6 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 2.2M | 770,000 | 1.4M | 470,000 | 470,000 | 0.561 |
| Q2 '25 | 1.7M | 770,000 | 960,000 | -13M | -2.9M | -60.980 |
| Q1 '25 | 1.9M | 840,000 | 1.1M | -3M | -3M | -0.690 |
| Q4 '24 | 2.3M | 820,000 | 1.5M | -1.5M | -2.2M | -0.440 |
| Q3 '24 | 2.4M | 710,000 | 1.7M | 2.4M | -1.5M | 1.740 |
Insider Transactions View All
| Jaramillo Nestor Jr. filed to buy 4,098 shares at $4.8. March 16 '23 |
Similar companies
Read more about Nuwellis (NUWE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Nuwellis
The Market Cap of Nuwellis is $2.2M.
As of today, Nuwellis' PE (Price to Earnings) ratio is 0.01.
Currently, the price of one share of Nuwellis stock is $1.26.
The NUWE stock price chart above provides a comprehensive visual representation of Nuwellis' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Nuwellis shares. Our platform offers an up-to-date NUWE stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Nuwellis (NUWE) does not offer dividends to its shareholders. Investors interested in Nuwellis should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Nuwellis are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
